Hyperfine, Inc.
HealthcareNASDAQ:HYPR · NASDAQ Global Market
-$0.06 today
Vol 0.46M · Avg 0.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-86.8%
avg -59.5%
ROIC
-84.7%
avg -60.6%
ROA
-64.4%
avg -51.6%
Analysis
ROA is currently the strongest return metric at -64.4% versus its period average of -51.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Maria Sainz | Chief Executive Officer, President & Director | $896,817.00 | — | 60 | $789,586.00 | 0.94% |
Brett Hale | Chief Administrative Officer, Chief Financial Officer, Chief Compliance Officer, Treasurer & Corporate Secretary | $799,634.00 | — | 52 | $599,765.00 | 0.71% |
Thomas Teisseyre | Chief Operating Officer | $799,634.00 | — | 42 | $678,601.00 | 0.81% |
Jonathan Rothberg | Founder & Vice Chairman | $50,000.00 | — | 62 | $157,700.00 | 0.19% |
Rafael O'Halloran | Vice President of Technology | — | — | — | — | — |
Rob Fasciano | Chief Regulatory & Quality Officer | — | — | — | — | — |
Rafael Donnay | Senior Vice President of Hospital Business | — | — | — | — | — |
Chip Truwit FACR | Senior Vice President of Office Strategy and Partnerships | — | — | — | — | — |
Edmond Knopp | Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$82,450.83
Net Sentiment
$82,450.83
Net selling
Most Active
TEISSEYRE THOMAS
5 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 7 sells worth $82,450.83 over the last 12 months. That adds up to net selling of $82,450.83. TEISSEYRE THOMAS was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +234.8% | +17.7% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +234.8% over three years. Forward estimates point to Revenue at +17.7% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Edap Tms S.a.
EDAP
$178.23M
Quipt Home Medical Corp.
QIPT
$162.30M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
FONAR Corporation
NASDAQ:FONR
$117.76M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Pulmonx Corporation
NASDAQ:LUNG
$57.86M
InspireMD, Inc.
NSPR
$34.19M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages HYPR?
Hyperfine, Inc. (HYPR) lists 9 active executives. The top listed executive is Rafael O'Halloran, Vice President of Technology.
Are HYPR insiders buying or selling?
Recent insider activity shows net buying of $20.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.